Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (291-300 of 419) with videos related to

Pageof 42
Sort By:
European Urology|July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 TrialMartin H Voss, Howard Gurney, Vagif Atduev, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|October 21, 2023
Genomic ancestry in kidney cancer: Correlations with clinical and molecular featuresRitesh R Kotecha, Andrea Knezevic, Kanika Arora, et al.
Urologic Oncology|December 22, 2023
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinomaStephen W Reese, Lennert Eismann, Charlie White, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
European Urology Oncology|November 19, 2019
The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive NephrectomyRenzo G DiNatale, Wanling Xie, Maria F Becerra, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell CarcinomaYash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
Pageof 42

Showing results (291-300 of 419) with videos related to

Sort By:
Pageof 42
European Urology|July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 TrialMartin H Voss, Howard Gurney, Vagif Atduev, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|October 21, 2023
Genomic ancestry in kidney cancer: Correlations with clinical and molecular featuresRitesh R Kotecha, Andrea Knezevic, Kanika Arora, et al.
Urologic Oncology|December 22, 2023
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinomaStephen W Reese, Lennert Eismann, Charlie White, et al.
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
European Urology Oncology|November 19, 2019
The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive NephrectomyRenzo G DiNatale, Wanling Xie, Maria F Becerra, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell CarcinomaYash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
Pageof 42